Spontaneous regression of a parafalcine meningioma in a multiple sclerosis patient being treated with interferon beta-1a

Galloway, Luke; Vakili, N Alizadeh; Spears, Julian

doi:10.1007/s00701-016-3019-6

Cited by 3 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…So far, 19 cases (male-female ratio 6:13) of spontaneous meningioma regression, including this case, have been reported [Table 1]. [3][4][5]7,8,10,11,13,19,[21][22][23][24][25] e average age was 54.7 (17-80) years at the time of tumor discovery, with a tendency to regress over several years. e sites of tumor development varied but appeared to be the same as in common meningiomas while only our case occurred in the posterior fossa.…”

Section: Discussionmentioning

confidence: 94%

Spontaneous regression of a posterior fossa meningioma: A case report

Takada

Yanaka

Nakamura

et al. 2022

Surgical Neurology International

View full text Add to dashboard Cite

Background: Since most incidentally discovered meningiomas grow or remain unchanged, spontaneous regression is extremely rare. Here, we report a case of posterior fossa meningioma showing spontaneous regression. Case Description: A 55-year-old female was referred to our hospital because she was diagnosed with a left posterior fossa meningioma (diameter: 1.6 cm) during a brain check-up. The patient was followed up on periodic magnetic resonance imaging studies. Tumor size remained almost unchanged for 2 years but then began to regress. Twelve years after the initial examination, the tumor diameter idiopathically decreased from 1.6 cm to 1.1 cm while the tumor volume decreased from 2.3 cm3 to 0.5 cm3 (about 1/4th the original size). Postmenopausal hormonal imbalances may have been associated with the observed spontaneous regression. Conclusion: Understanding the natural history of meningiomas is essential for a better selection of treatment approaches or appropriate follow-up. This case may provide new insights into the progression of meningiomas.

show abstract

Section: Discussionmentioning

confidence: 94%

Spontaneous regression of a posterior fossa meningioma: A case report

Takada

Yanaka

Nakamura

et al. 2022

Surgical Neurology International

View full text Add to dashboard Cite

show abstract

“…Moreover, we found in our sample that TIFN and TDMF protected against neoplasm development, although INF and GA have been linked to cancer development 9 , 25 – 27 . However, a regressive effect of IFN has been casually observed in isolated neoplasms 28 , as well as a 32% lower mortality related to untreated patients 29 . Regarding DMF, which was recently licensed, a few studies have been published with a short follow-up, confirming its safe use (cancer was detected in only 0.9% of patients) 30 .…”

Section: Discussionmentioning

confidence: 99%

Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients

Gil-Bernal

González-Caballero

Espinosa-Rosso

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Neoplasm development in Multiple Sclerosis (MS) patients treated with disease-modifying therapies (DMTs) has been widely discussed. The aim of this work is to determine neoplasm frequency, relationship with the prescription pattern of DMTs, and influence of the patients’ baseline characteristics. Data from 250 MS outpatients were collected during the period 1981–2019 from the medical records of the Neurology Service of the HUPM (Hospital Universitario Puerta del Mar)—in Southern Spain—and analysed using Cox models. Neoplasm prevalence was 24%, mainly located on the skin, with cancer prevalence as expected for MS (6.8%). Latency period from MS onset to neoplasm diagnosis was 10.4 ± 6.9 years (median 9.30 [0.9–30.5]). During the observation period β-IFN (70.4% of patients), glatiramer acetate (30.4%), natalizumab (16.8%), fingolimod (24.8%), dimethyl fumarate (24.0%), alemtuzumab (6.0%), and teriflunomide (4.8%) were administered as monotherapy. Change of pattern in step therapy was significantly different in cancer patients vs unaffected individuals (p = 0.011) (29.4% did not receive DMTs [p = 0.000]). Extended Cox model: Smoking (HR = 3.938, CI 95% 1.392–11.140, p = 0.010), being female (HR = 2.006, 1.070–3.760, p = 0.030), and age at MS diagnosis (AGE-DG) (HR = 1.036, 1.012–1.061, p = 0.004) were risk factors for neoplasm development. Secondary progressive MS (SPMS) phenotype (HR = 0.179, 0.042–0.764, p = 0.020) and treatment-time with IFN (HR = 0.923, 0.873–0.977, p = 0.006) or DMF (HR = 0.725, 0.507–1.036, p = 0.077) were protective factors. Tobacco and IFN lost their negative/positive influence as survival time increased. Cox PH model: Tobacco/AGE-DG interaction was a risk factor for cancer (HR = 1.099, 1.001–1.208, p = 0.049), followed by FLM treatment-time (HR = 1.219, 0.979–1.517). In conclusion, smoking, female sex, and AGE-DG were risk factors, and SPMS and IFN treatment-time were protective factors for neoplasm development; smoking/AGE-DG interaction was the main cancer risk factor.

show abstract

“…Z powodu działania na układ odpornościowy oraz z uwagi na brak dostępnych długoterminowych obserwacji ostrzeżenie o potencjalnym ryzyku raka pojawia się podczas stosowania takich leków, jak kladrybina, fingolimod, natalizumab lub alemtuzumab. Większość wymienionych prac nie uwzględnia jednak czynników takich, jak dieta, palenie tytoniu, promieniowanie słoneczne i terapia hormo-treatment was observed in 2017 in Vienna [16]. Reports on the occurrence of chronic myelogenous leukaemia during interferon beta-1a treatment can also be found in publications [17].…”

Section: Y S K U S Junclassified

“…W badanej grupie u pacjentki z oponiakiem mózgowia wzrost tego guza w trakcie terapii interferonem był tak szybki, że zdecydowano o zaprzestaniu terapii. Istnieją również pojedyncze doniesienia przeczące powyższym obserwacjom, mianowicie w opisie przypadku z Wiednia z 2017 r. zaobserwowano spontaniczną regresję oponiaka u pacjenta poddawanego terapii interferonem beta-1a [16]. W publikacjach można również znaleźć obserwacje wystąpienia przewlekłej białaczki szpikowej w trakcie leczenia interferonem beta-1a [17].…”

Section: O N C L U S I O N Sunclassified

Comorbidities in multiple sclerosis

Hercuń¹,

Tomaszewski²,

Juryńczyk³

2019

Ann. Acad. Med. Siles.

View full text Add to dashboard Cite

INTRODUCTION: Multiple Sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system, in which multifocal nerve tissue damage occurs. MATERIAL AND METHODS: The study analyzed the documentation of 130 patients hospitalized for multiple sclerosis in the Neurological Department of the Hospital in Bełchatów between I.2010 and V.2018. The control group were 177 patients from the Occupational Medicine Outpatient Clinic of the Medicall Health Institute in Piotrków Trybunalski consulted in 2018. RESULTS: Among patients with MS 49.2% were diagnosed with other diseases. The highest rate of comorbidity occurred in the primary progressive form and the lowest in the relapsing-remitting form. The most common diseases among MS patients were: arterial hypertension (23.8%), depression (9.2%), benign prostatic hyperplasia (7.7%), type 2 diabetes (6.9%), spinal discopathy (5.4%), cancer in anamnesis (3.8%)-2% were malignant tumors and 2% nonmalignant tumors, ischemic heart disease (3.1%), hypothyroidism (3.1%), psoriasis (3.1%), bronchial asthma (3.1%), ulcerative colitis (3.1%). Hyperlipidemia, which occurred in 35% of the subjects, was an important problem in patients with MS consisted, in the majority of cases, of elevated total and LDL cholesterol values. CONCLUSIONS: The most frequent comorbidities in MS patients are hyperlipidemia, hypertension, depression, benign prostatic hyperplasia, type 2 diabetes and spinal discopathy. The distribution of disease differed in individual forms of MS, however, this could be due to the age differences among patients. Researching the issue of comorbidity in MS is an important part of the integrated care as it can improve the treatment effectiveness in this group of patients.

show abstract

Spontaneous regression of a parafalcine meningioma in a multiple sclerosis patient being treated with interferon beta-1a

Cited by 3 publications

References 15 publications

Spontaneous regression of a posterior fossa meningioma: A case report

Spontaneous regression of a posterior fossa meningioma: A case report

Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients

Comorbidities in multiple sclerosis

Contact Info

Product

Resources

About